Nirsevimab immunization's real-world effectiveness in preventing severe bronchiolitis: A test-negative case-control study.

BACKGROUND: Several clinical trials have shown that nirsevimab, an antibody targeting the respiratory syncytial virus (RSV), reduces RSV bronchiolitis requiring admission. In 2023-2024, Catalonia and Andorra adopted immunization strategies for children <6 months and those born during the epidemic season. This study evaluates the effectiveness of nirsevimab in preventing hospitalizations from RSV bronchiolitis. METHODS: In the epidemic season of 2023-2024, a test-negative case-control study was conducted in three hospitals from Catalonia and Andorra. Patients <12 months old admitted with bronchiolitis and tested for RSV using molecular microbiology tests were included. The effectiveness in preventing RSV bronchiolitis hospitalization and severe disease was estimated using multivariate models. Comparisons between immunized, non-immunized, and non-eligible patients were made in prospectively collected epidemiological, clinical, and microbiological variables. RESULTS: Two hundred thirty-four patients were included. RSV was detected in 141/234 (60.2%), being less common in the immunized group (37% vs 75%, p < .001). The rate of immunized patients among those eligible was 59.7%. The estimated effectiveness for RSV-associated lower respiratory tract infection was 81.0% (95% confidence interval: 60.9-90.7), and for preventing severe disease (the need for NIV/CMV), 85.6% (41.7-96.4%). No significant differences by immunization status were observed in patients with RSV concerning viral coinfections, the need for NIV/CMV or length of hospital stay. CONCLUSIONS: This study provides real-world evidence of the effectiveness of nirsevimab in preventing RSV-lower respiratory tract infection hospitalization and severe disease in infants during their first RSV season following a systematic immunization program. Immunized patients did not exhibit a higher rate of viral coinfections nor differences in clinical severity once admitted.

[Acute sexual abuse in children and adolescents: a methodological contribution to improve the quality of care.] / Abuso sexual infanto-juvenil agudo: una aportación metodológica para mejorar la calidad asistencial.

OBJECTIVE: The complexity of consultations for child and adolescent sexual abuse (CSA), added to the high service pressure in Emergency Department (ED), makes legal proceedings to be prioritized over medical action, and security incidents may appear. Our objective was to evaluate the impact of a checklist for the management of acute CSA in ED, assessing the number and type of security incidents. METHODS: A single-centre, descriptive-observational study was conducted between 2018 in ED. Clinical, epidemiological and follow-up data were collected in those patients younger than 18 that were reported as acute CSA suspicions. Incidents about clinical history, procedures and medication were analyzed. The sample were divided in two groups in relation the use of checklist (Group1: January-May and Group 2: June-December). RESULTS: Thirty-two patients were included: 13 Group 1, 19 Group 2. In 25 (78.1%) incidents were detected from the clinical history, in 20 (56.3%) from procedures and in 5 (15.5%) from medication. One-hundred by one-hundred clinical history incidents and 100% procedural incidents were observed in Group 1 vs 63.2% and 36.8% in Group 2 (p=0.025 y p=0.007) and 30.8% of medication incidents in Group 1 vs 5.3% in Group 2 (p=0.051). CONCLUSIONS: The implementation of the checklist has led to an improvement in the medical care of patients with acute CSA with a decrease in security incident.

OBJETIVO: La complejidad de las consultas por abuso sexual infantojuvenil (ASI) sumada a la presión asistencial en el servicio de urgencias (SU) hace que se prioricen las diligencias legales a la actuación médica pudiendo aparecer incidentes de seguridad. El objetivo de este trabajo fue evaluar el impacto de un checklist para el manejo de ASI en el SU valorando el número y tipo de incidentes de seguridad. METODOS: Estudio unicéntrico, descriptivo-observacional. Se recogieron datos clínicos, epidemiológicos y de seguimiento de todos los pacientes menores de 18 años que fueron atendidos en el SU por sospecha de ASI agudo durante 2018. Se analizaron los incidentes de la historia clínica, procedimientos y medicación. La muestra se dividió en dos grupos en relación al inicio del uso del checklist en el SU (Grupo: Enero-mayo y Grupo 2: junio-diciembre). RESULTADOS: Se incluyeron 32 casos: 13 Grupo 1, 19 Grupo 2. En 25 (78,1%) se detectaron incidentes de historia clínica, en 20 (56,3%) de procedimiento y en 5 (15,5%) de medicación. Se observaron 100% de incidentes tanto de historia clínica como de procedimiento en el Grupo 1 vs 63,2% y 36,8% respectivamente en el Grupo 2 (p=0,025 y p=0,007) y 30,8% de medicación en Grupo 1 vs 5,3% en Grupo 2 (p=0,051). CONCLUSIONES: La implantación del checklist ha supuesto una mejora en la atención médica de los pacientes con ASI agudo, con una disminución de los incidentes de seguridad.